Skip to main content
Lanzhou Foci Pharmaceutical Co.,Ltd. logo

Lanzhou Foci Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 002644 ISIN · CNE1000019W4 LEI · 3003003631P3BQOCH698 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,294 across all filing types
Latest filing 2026-05-12 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002644

About Lanzhou Foci Pharmaceutical Co.,Ltd.

https://www.fczy.com

Lanzhou Foci Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of Traditional Chinese Medicine (TCM). Established in 1929, the company is historically significant for pioneering the industrial manufacture of concentrated TCM pills. Its extensive product portfolio features proprietary Chinese medicines, including Liuwei Dihuang Wan and Xiaoyao Wan, alongside various herbal extracts and health products. The company utilizes modern manufacturing infrastructure to integrate traditional herbal formulas with advanced pharmaceutical technologies. Lanzhou Foci emphasizes quality control through standardized production processes and rigorous testing protocols. Its market reach extends from domestic distribution to international exports, supporting the global presence of traditional herbal remedies. The company is characterized by its heritage as a time-honored brand dedicated to the modernization of herbal medicine.

Recent filings

Filing Released Lang Actions
第八届董事会第十六次会议决议公告
Board/Management Information Classification · 82% confidence The document is an announcement of the Board of Directors’ meeting resolutions (time, attendance, proposals reviewed, and voting results) rather than a financial report, legal proceeding, share transaction, or dividend notice. It falls under corporate governance/board information. The closest specific category is Board/Management Information (MANG).
2026-05-12 Chinese
关于召开2026年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal notice of the company’s 2026 second extraordinary shareholders meeting, detailing meeting date/time, venue, agenda items, voting methods, registration procedures, and includes a proxy form. It is sent to shareholders to provide information and solicit votes. This matches the Proxy Solicitation & Information Statement category.
2026-05-12 Chinese
董事、高级管理人员薪酬管理制度（2026年5月）
Governance Information Classification · 85% confidence The document is titled “董事、高级管理人员薪酬管理制度” and lays out the internal rules, principles, and procedures for determining and managing board and senior management compensation. It is a governance policy/manual rather than an actual financial report, remuneration disclosure statement, or proxy filing. This aligns with Governance Information (CGR) under our taxonomy, which covers detailed internal rules and governance practices.
2026-05-12 Chinese
2025年年度股东会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 Annual General Meeting (AGM) of 兰州佛慈制药股份有限公司. It includes voting results on various agenda items such as the 2025 board work report, financial statements, profit distribution plan, internal control evaluation, amendments to governance policies, and executive compensation. The document also mentions the presence of independent directors' reports and legal opinions confirming the legality and validity of the meeting and its resolutions. The content focuses on the official voting results and decisions made at the AGM rather than the full annual report or financial statements themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains substantive voting data, so it is not a mere announcement of report publication or a regulatory filing. Hence, the classification is DVA with high confidence.
2026-05-08 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 92% confidence The document is a "专项审核报告" (special audit report) issued by an accounting firm (Zhongshenzbonghuan Certified Public Accountants) on non-operating funds occupy and related-party fund transactions for Lanzhou Foci Pharmaceutical Co., Ltd. It contains audit procedures, audit opinion, and detailed summary tables. It is a standalone audit report, not an Annual Report or announcement. Therefore it matches the "Audit Report / Information" category (Code: AR). FY 2025
2026-04-08 Chinese
财务负责人管理制度（2026年4月）
Governance Information Classification · 95% confidence The document is titled '财务负责人管理制度' which translates to 'Financial Officer Management System'. It outlines the qualifications, responsibilities, appointment, and accountability of the company's financial officer. The content is a detailed internal policy or governance document related to the management and duties of a senior financial executive. It does not contain financial statements, audit results, earnings data, or any report publication announcements. It is not a regulatory filing or certification. The document fits best under governance-related information about company management practices and internal rules. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4118 characters, which is substantial and contains detailed governance content rather than a brief announcement or report publication notice.
2026-04-08 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.